Yield10 Bioscience, Inc. (OTCQB:YTEN) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Lynne Brum – Vice President of Planning and Corporate Communications Oli Peoples – Chief Executive Officer Kristi Snell – Vice President of Research and Chief Science Officer Chuck Haaser – Chief Accounting Officer Conference Call Participants Anthony Vendetti – Maxim Group Operator Welcome to the Second Quarter 2023 Financial Results and Business Update Conference Call for Yield10 Bioscien ...

| Yield10 Second Quarter 2023 Financial Results and Business Highlights Today August 14, 2023 Yield10 Bioscience, Inc. www.yield10bio.com NasdaqCM: YTEN Sustainable Growth Starts with a Seed Safe Harbor Statement Today 2 The statements made by Yield10 Bioscience, Inc. (the "Company," "we," "our" or "us") herein regarding the Company and its business may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking st ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33133 YIELD10 BIOSCIENCE, INC. (State or other jurisdiction of incorporation or organization) 19 Presidential Way Woburn, MA 01801 (Address ...

Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 Commission file number 001-33133 YIELD10 BIOSCIENCE, INC. (State or other jurisdiction of incorporation or organization) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 19 Presidential Way Woburn, MA 01801 (Addres ...

Yield10 First Quarter 2023 Financial Results and Business Highlights Today May 10, 2023 Yield10 Bioscience, Inc. www.yield10bio.com NASDAQ: YTEN Sustainable Growth Starts with a Seed Safe Harbor Statement* Today 2 The statements made by Yield10 Bioscience, Inc. (the "Company," "we," "our" or "us") herein regarding the Company and its business may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statement ...

Yield10 Bioscience, Inc. (OTCQB:YTEN) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Lynne Brum - Vice President of Planning and Corporate Communications Oliver Peoples - President and Chief Executive Officer Kristi Snell - Vice President of Research and Chief Science Officer Chuck Haaser - Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Anthony Vendetti - Maxim Group Sameer Joshi - H.C. Wainwright Operator Welcome to the First Qu ...

Yield10 Bioscience, Inc. (OTCQB:YTEN) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Lynne Brum – Vice President of Planning and Corporate Communications Oliver Peoples – President and Chief Executive Officer Kristi Snell – Vice President of Research and Chief Science Officer Chuck Haaser – Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Anthony Vendetti - Maxim Group Sameer Joshi - H.C. Wainwright Operator Greeting and welcome ...

Yield10 Yield10 Bioscience, Inc. www.yield10bio.com NASDAQ: YTEN Fourth Quarter and Full Year 2022 Financial Results and Business Highlights Today March 14, 2023 Sustainable Growth Starts with a Seed Safe Harbor Statement* Today 2 The statements made by Yield10 Bioscience, Inc. (the "Company," "we," "our" or "us") herein regarding the Company and its business may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward- ...

40Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33133 YIELD10 BIOSCIENCE, INC. (Exact name of registrant as specifie ...

Yield10 Bioscience, Inc. (OTCQB:YTEN) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Lynne Brum – Vice President of Planning and Corporate Communications Oliver Peoples – President and Chief Executive Officer Kristi Snell – Vice President of Research and Chief Science Officer Chuck Haaser – Chief Accounting Officer Conference Call Participants Anthony Vendetti – Maxim Group Ben Klieve – Lake Street Capital Markets Operator Welcome to the Third Quarter 2022 Financial Resul ...